Clinical-stage biopharmaceutical company developing psychedelic-inspired medicines.
2 AI-extracted insights from 2 sources — podcasts, YouTube channels, and X/Twitter accounts.
Based on 1 scored insight about Mind Medicine (MindMed) Inc..
The 2 sources with the most insights about Mind Medicine (MindMed) Inc. on Kazuha.
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
Advancing Phase 3 clinical trials using pharmaceutical-grade LSD for generalized anxiety disorder with strong efficacy over standard SSRIs.
Highly bullish following 'very convincing' Phase 3 results for an LSD-like product; upcoming psilocybin results in August are a major catalyst.
Advancing Phase 3 clinical trials using pharmaceutical-grade LSD for generalized anxiety disorder with strong efficacy over standard SSRIs.
Highly bullish following 'very convincing' Phase 3 results for an LSD-like product; upcoming psilocybin results in August are a major catalyst.
Other assets that creators frequently mention in the same content as Mind Medicine (MindMed) Inc..
The most active sources covering Mind Medicine (MindMed) Inc. (MNMD) on Kazuha are @realmartinshkreli, @realvisionfinance. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
Kazuha has indexed 2 AI-extracted insights about Mind Medicine (MindMed) Inc. (MNMD) from 2 different sources. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
Creators covering Mind Medicine (MindMed) Inc. (MNMD) most frequently also discuss SPRB, COHR, ENVB, FN, LITE. See the "Discussed alongside" section above for full asset pages.